Mucosal healing of small intestinal stricture is associated with improved prognosis post-dilation in Crohn’s disease

Table 4 Logistic regression model showing the odds ratios for redilation in patients undergoing follow-up endoscopy (n = 71)

Variables at diagnosis		Case of redilation, n	Univariate			Multivariate
Variables at diagnosis		Case of redilation, n	OR	95% CI	p value	OR	95% CI	p value
Sex
Men	ref	44	1.00			1.00
Women		9	0.72	0.19, 2.69	0.620	0.56	0.13, 2.45	0.445
Age at diagnosis of CD
< 17		7	2.27	0.25, 20.37	0.464	3.81	0.35, 40.91	0.270
17–40	ref	37	1.00			1.00
40 <		9	0.58	0.16, 2.08	0.407	0.62	0.15, 2.47	0.495
Smoking
Never	ref	37	1.00
Current		8	0.48	0.13, 1.75	0.264
Ex-smoker		8	1.19	0.22, 6.44	0.841
Previous intestinal resection
No	ref	32	1.00
Yes		21	1.03	0.34, 3.09	0.956
Perianal involvement
No	ref	35	1.00
Yes		18	1.34	0.41, 4.34	0.629
Disease location
L1	ref	28	1.00
L3		25	1.79	0.58, 5.47	0.310
CDAI score
< 150	ref	47	1.00
≥ 150		6	0.64	0.14, 2.87	0.558
CRP at time of EBD
≤ 4 mg/L	ref	42	1.00
> 4 mg/L		11	0.92	0.25, 3.34	0.895
Endoscopic findings
Stricture length
< 2 cm	ref	51	1.00
≥ 2 cm		2	0.31	0.04, 2.41	0.265
Anastomotic site stricture
No	ref	48	1.00
Yes		5	0.83	0.15, 4.72	0.837
Location of stricture
TI	ref	14	1.00
PI		35	0.33	0.07, 1.65	0.178
J		4	0.57	0.04, 8.05	0.678
Presence of ulcer at the stricture
No	ref	15	1.00			1.00
Yes		38	5.07	1.61, 15.97	0.006*	5.69	1.72, 18.80	0.004*
Concomitant treatment
Corticosteroid
No	ref	47	1.00
Yes		6	0.64	0.14, 2.87	0.558
5-aminosalicylate
No	ref	19	1.00
Yes		34	0.89	0.29, 2.77	0.847
Anti-TNF
No	ref	24	1.00
Yes		29	1.90	0.64, 5.65	0.249
Immunomodulator
No	ref	31	1.00
Yes		22	2.48	0.72, 8.57	0.150
Anti-TNF + Immunomodulator
No	ref	42	1.00
Yes		11	4.45	0.53, 37.2	0.168

ref reference, EBD endoscopic balloon dilation, CD Crohn’s disease, CDAI Crohn’s disease activity index, CRP C-reactive protein, TI terminal ileum, PI proximal ileum, J jejunum, TNF tumor necrosis factor, OR odds ratio, CI confidence interval. *p < 0.05

ISSN: 1471-230X